Special Issue

Nanoparticle-Based Delivery Systems for Vaccines

Message from the Guest Editor

Developing advanced vaccines is crucial for effectively combating human and animal diseases and improving global well-being. Nanotechnology has significantly enhanced vaccine design, resulting in innovative approaches such as virus-like particle (VLP)-based vaccines, RNA vaccines, and new adjuvants that boost vaccine efficacy. This Special Issue aims to include advancements in vaccine efficacy achieved through nanomaterials to deliver protective antigens. It will also examine vaccine antigens with advantages such as easy purification and high immunogenicity. Additionally, the issue will explore nanomaterials used for alternative routes of administration, particularly those for mucosal vaccines, which hold promise for achieving protective immunity against various diseases. Furthermore, nanoparticles with immunostimulatory properties that can serve as vaccine adjuvants are also interesting. We encourage original research articles and reviews covering research areas that may include antigen delivery using nanomaterials, nano-adjuvants, innovative vaccine antigens, and multifunctional nanoparticles. We look forward to receiving your contributions.

Guest Editor

Dr. Sergio Rosales-Mendoza

Biotechnology Section, Center for Research in Health Science and Biomedicine, Autonomous University of San Luis Potosí, Av. Sierra Leona 550, Lomas de San Luis, San Luis Potosí 78210, Mexico

Deadline for manuscript submissions

28 February 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/216089

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI